Structural biologists have successfully characterized SARS-CoV-2 proteins that represent viable drug targets for structure-based computational design of new drugs, and for rapid repurposing of existing drugs for treatment of COVID-19. There has been extensive research into drugs that might interfere in the SARS-CoV-2 spike protein's interaction with its cognate human receptor, angiotensin-converting enzyme 2 (ACE2). Other heavily studied targets are the viral 3CL main protease (M pro , nsp5), PL protease (PL pro , nsp3), and RNA-dependent RNA polymerase (RdRp, major protein nsp12) . However, less attention has been paid to other potential target proteins such as the SARS-CoV-2 helicase, the focus of the current study.